DaVita Inc. (NYSE:DVA) Shares Sold by Cinctive Capital Management LP

Cinctive Capital Management LP lowered its stake in shares of DaVita Inc. (NYSE:DVA) by 24.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,357 shares of the company’s stock after selling 15,210 shares during the quarter. Cinctive Capital Management LP owned approximately 0.06% of DaVita worth $6,933,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of DVA. Amundi raised its stake in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after purchasing an additional 240,126 shares during the last quarter. FMR LLC raised its position in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of DaVita by 256.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after acquiring an additional 116,758 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in shares of DaVita by 75.1% during the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company’s stock worth $29,430,000 after purchasing an additional 84,375 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of NYSE:DVA opened at $151.82 on Wednesday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The business’s fifty day moving average price is $156.77 and its two-hundred day moving average price is $157.44. The stock has a market cap of $12.15 billion, a PE ratio of 14.14, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60.

DaVita (NYSE:DVA) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. StockNews.com lowered DaVita from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and an average target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.